GLP-1 has several functions, including: triggering the release of insulin from the pancreas controlling blood sugar levels slowing stomach emptying increasing the feeling of fullness after eating By mimicking the effects of GLP-1, semaglutide, helps to: control the amount of sugar in your blood keep you feeling full, reducing cravings and hunger reduce your calorie intake (by making it easier to eat less) Manufacturer Novo Nordisk manufactures both Ozempic and Wegovy
Semaglutide primarily works by reducing appetite and calorie intake, which forces your body to mobilize stored fat for energy
Coverage varies by province
Initially approved as Ozempic in 2017, it catered to adults living with Type 2 diabetes in the form of a once-weekly injection
These medications belong to a class called GLP-1 receptor agonists, which not only lower blood sugar but also promote weight loss by reducing appetite and increasing feelings of fullness
There are some concerns that semaglutide could reduce muscle mass and bone density, though were still learning more about this